Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
152
-
Total 13F shares, excl. options
-
29.6M
-
Shares change
-
+2M
-
Total reported value, excl. options
-
$916M
-
Value change
-
+$54M
-
Put/Call ratio
-
1.54
-
Number of buys
-
80
-
Number of sells
-
-82
-
Price
-
$31.53
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2020
218 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2020.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 152 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.6M shares
of 207M outstanding shares and own 14.25% of the company stock.
Largest 10 shareholders include Bellevue Group AG (5.04M shares), Meditor Group Ltd (2.68M shares), VANGUARD GROUP INC (2.48M shares), Pentwater Capital Management LP (2.31M shares), BlackRock Inc. (1.95M shares), MARSHALL WACE, LLP (1.32M shares), STATE STREET CORP (1.11M shares), BOXER CAPITAL, LLC (975K shares), WASATCH ADVISORS INC (906K shares), and CREDIT SUISSE AG/ (892K shares).
This table shows the top 152 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.